注射用重组人Ⅱ型肿瘤坏死因子受体-抗体融合蛋白治疗风湿免疫疾病的效果分析

Analysis of clinical effect on etanercept in rheumatic diseases treatment

目的分析注射用重组人Ⅱ型肿瘤坏死因子受体-抗体融合蛋白（肿瘤坏死因子抑制剂）治疗风湿免疫疾病的临床疗效及其意义,并进行安全性评价。方法选择2011年1月-2014年1月收治的86例风湿关节炎患者临床资料,采用随机数表方法将其随机分成两组,对照组43例患者采用传统西药进行治疗,观察组43例患者在对照组患者治疗方法基础上给予注射用重组人Ⅱ型肿瘤坏死因子受体-抗体融合蛋白进行治疗,比较两组患者的临床疗效及其不良反应情况。结果两组患者经过临床治疗,对照组患者的临床治疗的总有效率为81.39%（35/43）,观察组患者的临床治疗的总有效率为95.35%（41/43）,差异具有统计学意义（P〈0.05）;对照组患者的临床治疗的不良反应发生率为6.98%（3/43）,观察组患者的临床治疗的总有效率为4.65%（2/43）,差异无统计学意义（P〉0.05）。结论本研究结果表明,临床上对于风湿免疫性疾病患者在常规西药治疗方法的基础上联合给予注射用重组人Ⅱ型肿瘤坏死因子受体-抗体融合蛋白进行治疗能取得较好的临床疗效,该方法临床疗效确切,临床不良反应小,显著改善患者的生活质量,因此值得临床推广使用。

Objective To observe the clinical effect of using etanercept（Department of internal medicine clinical tumor necrosis factor inhibitors） in the treatment of autoimmune rheumatic diseases.To evaluate its safety. Methods 86 patients from July 2011 to July 2014 were randomly divided into two groups. 43 cases in the control group were treated with traditional western medicine treatment,43 patients in the control group were treated with etanercept treatment method.It was based on the comparison of adverse reaction, and the clinical efficacy of two groups patients condition. Results After treatment the two groups of patients, the total effective rate in the treatment group was 81.39%（35/43）, the total effective rate of clinical observation of patients in the treatment group was 95.35%（41/43）.There were significant differences between the two groups（P〈0.05）.The adverse reaction in treatment group of patients was 6.98%（3/43）, clinical observation of patients in the treatment group was 4.65%（2/43）. There were no significant differences between the two groups（P 〉0.05）. Conclusion The results of this study shows： clinical patients for autoimmune rheumatic diseases based on conventional western medicine, in the treatment of combined administration of etanercept, can obtain good clinical curative effect. the clinical effect is exact. clinical adverse reactions improve the quality of life. It is worthy of clinical use.